Expertise in
9
conditions

Dr. Charles B. Simone

Hematology | Oncology
Office
123 Franklin Corner Rd Ste 108, 
Lawrence Township, NJ 
Expertise in
9
conditions
Office
123 Franklin Corner Rd Ste 108, 
Lawrence Township, NJ 

Overview

Charles Simone is a Hematologist and an Oncologist practicing medicine in Lawrence Township, New Jersey.

Dr. Simone is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Thymectomy, and Prostatectomy.

He is actively involved in clinical research, co-authoring 672 peer reviewed articles and participating in 11 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in NJ

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Independent Health
  • EPO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

Office
123 Franklin Corner Rd Ste 108, Lawrence Township, NJ 08648

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

LCI-LUN-NSC-SBRT-001: Phase II Prospective Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation and Adjuvant Immunotherapy for Locally-Advanced Non-Small Cell Lung Cancer
LCI-LUN-NSC-SBRT-001: Phase II Prospective Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation and Adjuvant Immunotherapy for Locally-Advanced Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2026
Intervention Type: Drug, Radiation
Study Drugs: Carboplatin, Paclitaxel, cis Platinum, Etoposide, Durvalumab
Study Phase: Phase 2
Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases
Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2026
Intervention Type: Other
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Other, Drug, Biological, Radiation
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Human Blood Collection to Serve as Negative Control for Validation of Circulating Tumor Cell Assay
Human Blood Collection to Serve as Negative Control for Validation of Circulating Tumor Cell Assay
Enrollment Status: Completed
Publish Date: January 29, 2026
Intervention Type: Other
Moving PD-1 Blockade With Pembrolizumab Into Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Moving PD-1 Blockade With Pembrolizumab Into Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 16, 2025
Intervention Type: Radiation, Drug, Other, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 1
The Detection Of Circulating Tumor Cells (CTC) In Patients With Non-small Cell Lung Cancer (NSCLC) Undergoing Definitive Radiotherapy Or Chemoradiotherapy
The Detection Of Circulating Tumor Cells (CTC) In Patients With Non-small Cell Lung Cancer (NSCLC) Undergoing Definitive Radiotherapy Or Chemoradiotherapy
Enrollment Status: Completed
Publish Date: November 20, 2024
Intervention Type: Radiation
A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)
A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: January 25, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
Cardiac Magnetic Resonance Imaging and Biomarker Testing for Evaluating Cardiac Injury Resulting From Radiation Therapy in Cancer: A Pilot Study
Cardiac Magnetic Resonance Imaging and Biomarker Testing for Evaluating Cardiac Injury Resulting From Radiation Therapy in Cancer: A Pilot Study
Enrollment Status: Terminated
Publish Date: October 13, 2022
Intervention Type: Other
A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy
A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy
Enrollment Status: Completed
Publish Date: July 22, 2022
Intervention Type: Diagnostic test
Study Phase: Not Applicable
View 9 Less Clinical Trials

672 Total Publications

A literature review and reflection on clinical trials: current challenges, future directions, and potential strategies to overcome practical barriers.
A literature review and reflection on clinical trials: current challenges, future directions, and potential strategies to overcome practical barriers.
Journal: AME clinical trials review
Published: August 18, 2026
Similar Doctors
Expertise in
26
conditions
Dr. Matthew J. Matasar
Hematology | Oncology
Expertise in
26
conditions
Dr. Matthew J. Matasar
Hematology | Oncology
Referral may be required

Rutgers Cancer Institute Of New Jersey

195 Little Albany St, 
New Brunswick, NJ 
 (20.4 miles away)
732-475-0824
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Matasar is a Hematologist and an Oncologist practicing medicine in New Brunswick, New Jersey. Dr. Matasar is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, B-Cell Lymphoma, and Bone Marrow Transplant. Dr. Matasar is currently accepting new patients.

Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (52.3 miles away)
646-535-8986
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Horwitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Horwitz is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Horwitz is currently accepting new patients.

Expertise in
27
conditions
Dr. Gilles A. Salles
Hematology | Oncology
Expertise in
27
conditions
Dr. Gilles A. Salles
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (52.3 miles away)
929-298-9410
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gilles Salles is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Salles is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Bone Marrow Transplant, and Splenectomy. Dr. Salles is currently accepting new patients.

Frequently Asked Questions about Dr. Charles B. Simone

How do I make an appointment with Dr. Charles B. Simone?

You can book an appointment with Dr. Charles B. Simone by calling their office at 609-896-2646. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Charles B. Simone a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Charles B. Simone is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Charles B. Simone specialize in?

While Dr. Charles B. Simone is a Hematology, they have specific expertise in Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Mesothelioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Charles B. Simone participate in research or clinical trials?

Yes. Dr. Charles B. Simone has published 672 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Charles B. Simone's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Charles B. Simone accept my insurance?

Dr. Charles B. Simone accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 609-896-2646 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Simone's expertise for a condition
ConditionClose
    View All 36 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile